Logo

Baylor Genetics ClariFind

Mar 06, 2018

Baylor Genetics has launched ClariFind, a somatic tumor next-generation sequencing test that analyzes alterations in 277 cancer genes for both solid tumors and hematologic malignancies. The test uses molecular indexing prior to PCR and sequencing to enable the detection of low-frequency mutations. The ClariFind report provides annotated genomic findings, any associated targeted therapies and available clinical trials, and an interpretative summary.

Breaking News
The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.